IsoRay (ISR) Aandeel Koers
IsoRay Koers
De omzet is de afgelopen 16 jaar met 11,1% per jaar gegroeid tot 10,80 Miljoen USD. De nettowinstmarge van IsoRay ligt op -66,3% en is ten opzichte van -113,1% enkele jaren eerder gestegen. Van de 6 analisten geven 5 het aandeel een koopadvies — per saldo een Kopen-consensus.
IsoRay aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
IsoRay bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over IsoRay
IsoRay Inc is a renowned company that specializes in the development and commercialization of innovative solutions for the treatment of cancer and other diseases. Its business model revolves around the research, production, and distribution of brachytherapy products. These products involve the use of radiation therapy, specifically Cesium-131, to target and destroy cancer cells while minimizing damage to healthy tissues. By offering safe and effective treatment options, IsoRay Inc aims to improve patient outcomes and enhance the quality of life for individuals battling cancer. With its focus on cutting-edge brachytherapy technologies, IsoRay Inc continues to advance the field of oncology and contribute to the fight against cancer.
IsoRay Inc is primarily active in the medical industry. With a focus on innovative advancements in brachytherapy, IsoRay Inc specializes in the production and sale of personalized cancer treatment solutions. This dynamic company operates within the healthcare sector, providing cutting-edge IsoRay Cesium-131 seed technology for the treatment of various forms of cancer. Through its industry expertise and dedication to improving patient outcomes, IsoRay Inc has gained recognition as a leading player in the medical field.
Some of the main competitors of IsoRay Inc in the market include Varian Medical Systems, Eckert & Ziegler BEBIG, and Elekta AB.
IsoRay Inc is a renowned company specializing in personalized internal radiation therapy products. Established in 1998, IsoRay has since become a prominent player in the medical industry. The company is dedicated to providing innovative solutions for cancer treatment, particularly in the field of brachytherapy. IsoRay Inc has developed and commercialized Cesium-131, a radiation isotope that offers superior treatment outcomes for various cancer types. With a steadfast commitment to improving patients' quality of life, IsoRay continues to lead the way in radiation therapy advancements. With its rich history and expertise, IsoRay Inc remains at the forefront of the fight against cancer.
IsoRay Inc has achieved several significant milestones. The company specializes in innovative brachytherapy solutions for the treatment of cancer. Over the years, IsoRay Inc has successfully developed and commercialized its proprietary Cesium-131 (Cs-131) brachytherapy seeds, which have been widely recognized for their effectiveness in treating prostate, brain, lung, and other cancers. IsoRay Inc has also obtained FDA clearance for its novel GammaTile® Therapy, a radiation treatment for brain tumors. Moreover, the company has expanded its global presence, establishing partnerships with healthcare providers and achieving regulatory approvals in multiple countries. These milestones highlight IsoRay Inc's dedication to improving cancer care through cutting-edge technologies and expanding its reach in the healthcare industry.
IsoRay Inc is primarily present in the United States.
IsoRay Inc represents a strong commitment to improving the lives of cancer patients through its innovative products and solutions. The company's corporate philosophy revolves around delivering cutting-edge brachytherapy solutions that offer precise, targeted cancer treatment. IsoRay Inc values integrity, quality, and teamwork, striving to provide physicians and patients with reliable and effective solutions for various cancer types. With its pioneering Cesium-131 brachytherapy seeds, IsoRay Inc aims to revolutionize cancer therapy by providing superior outcomes and enhancing patients' quality of life. The company's dedication to technological advancements and patient-centric approach sets it apart in the healthcare industry.
6 analisten beoordelen het aandeel IsoRay momenteel: 5 adviseren kopen, 1 houden en 0 verkopen.
Het aandeel IsoRay (ISR) is genoteerd aan 6 beurzen, waaronder: NYSE (CATX), Frankfurt (AAJ.F), München (AAJ.MU), Stuttgart (AAJ.SG), Berlin (AAJ.BE).
IsoRay Inc is a medical technology company based in Richland, Washington, USA. The company is the leading provider of innovative brachytherapy products. Brachytherapy is a method used in the treatment of cancer, where the radioactive source is directly placed into the cancer cells. IsoRay operates in two main business segments. The first segment focuses on the sale of Prostate Seed Implants. These implants are used in the treatment of prostate cancer and are IsoRay's flagship product. Implants provide better treatment by delivering a high dose of radiation directly to the cancer cells while protecting the surrounding organs and tissues. The implants consist of small radiation sources that are placed into the prostate. Brachytherapy is an alternative to other treatments such as surgery or radiation therapy. The implant is inserted by specially trained surgeons, and IsoRay provides support and training for medical personnel. IsoRay's second business segment focuses on the development and marketing of radioactive plaques and radiation sources. These products can be used in the treatment of brain cancer, lung cancer, and other types of cancer. The radioactive plaques are surgically implanted and deliver radiation directly to the tumor. The radiation sources are used in brachytherapy to ensure precise treatment. IsoRay has established itself as a market leader in brachytherapy products. The company aims to provide its customers with precise treatments while preserving the surrounding tissues and organs. The company collaborates closely with the medical community and research institutions to continually improve its products and technologies. IsoRay also has a number of patents that protect the effectiveness of its products and increase competitiveness. IsoRay operates an effective marketing and distribution program to make its products known in the medical community. The company works with healthcare facilities and offers training and support to ensure that its products are well understood and used. IsoRay also utilizes online marketing to create direct demand among patients and healthcare professionals. IsoRay's business model focuses on the development and marketing of brachytherapy products, particularly Prostate Seed Implants. The company is a market leader in this field and continues to strive to develop innovative technologies and provide precise, gentle treatments. The close collaboration with the medical community, the marketing and distribution initiatives, and the patent applications have helped the company grow in this lucrative market.
De omzet kan momenteel niet worden berekend voor IsoRay.
De winst kan momenteel niet worden berekend voor IsoRay.
De P/E-ratio kan momenteel niet worden berekend voor IsoRay.
De P/S-ratio kan momenteel niet worden berekend voor IsoRay.
De Eulerpool Kwaliteitsscore voor IsoRay is 6/10.
De ISIN van IsoRay is US46489V1044. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van IsoRay is A0MQNM. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van IsoRay is ISR. Onder dit beurstickersymbool wordt het IsoRay-aandeel op de beurs verhandeld.
IsoRay aandeel
IsoRay Ticker
IsoRay FIGI
Alle fundamentals en diepgaande analyse van IsoRay
Onze aandelenanalyse van het IsoRay-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van IsoRay. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: